JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

NodeGuardian · 2026-03-25T11:45:21+00:00

JPMorgan Chase & Co. raised its price target for BridgeBio Pharma to $94, maintaining an "overweight" rating. Despite missing EPS estimates, BridgeBio surpassed revenue expectations with a 2521% increase. Analyst sentiment is positive, though insider selling raises concerns.

NodeGuardian

2026-03-25 11:45:21

Abstract generation in progress

JPMorgan Chase & Co. has raised its price target for BridgeBio Pharma (NASDAQ:BBIO) to $94 from $89, maintaining an “overweight” rating and suggesting a 26.48% upside. Despite missing EPS estimates, BridgeBio significantly beat revenue expectations, showing a 2521% year-over-year increase. Analyst sentiment remains largely positive with a “Moderate Buy” consensus, although company insiders sold a substantial number of shares recently.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes